MNG779
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.347
- HEDGEHOG_SIGNALING+0.227
- KRAS_SIGNALING_DN+0.227
- IL6_JAK_STAT3_SIGNALING+0.201
- TNFA_SIGNALING_VIA_NFKB+0.155
- INFLAMMATORY_RESPONSE+0.145
- MYOGENESIS+0.126
- HYPOXIA+0.114
- MITOTIC_SPINDLE+0.105
- INTERFERON_GAMMA_RESPONSE+0.091
Top 10 suppressed
- MYC_TARGETS_V1-0.648
- OXIDATIVE_PHOSPHORYLATION-0.605
- PROTEIN_SECRETION-0.575
- MTORC1_SIGNALING-0.440
- CHOLESTEROL_HOMEOSTASIS-0.417
- ADIPOGENESIS-0.407
- FATTY_ACID_METABOLISM-0.404
- DNA_REPAIR-0.379
- ANDROGEN_RESPONSE-0.371
- UNFOLDED_PROTEIN_RESPONSE-0.334
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NH7K4CD9 | Posterior Fossa Ependymoma | — | 0.890 |
| 2 | BS_NH7K4CD9 | EPN | Posterior Fossa EPN | 0.890 |
| 3 | SRR6013529 | — | cohortMD2 | 0.861 |
| 4 | SRR1375271 | GTEX | — | 0.859 |
| 5 | BS_0XEG6SNV | EPN | Supratentorial EPN | 0.851 |
| 6 | SRR6013548 | — | cohortA1 | 0.849 |
| 7 | 95d76fd3-540d-4c50-9ea9-b50fe2c37639 | — | — | 0.840 |
| 8 | SRR13311176 | — | — | 0.839 |
| 9 | SRR6013550 | — | cohortA1 | 0.837 |
| 10 | R116 | — | — | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.347 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.227 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.227 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.201 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.155 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.145 | Idelalisib | — uncovered |
| MYOGENESIS | 0.126 | Inavolisib | — uncovered |
| HYPOXIA | 0.114 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.105 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.091 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.087 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.042 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.038 | Inavolisib | — uncovered |
| COAGULATION | 0.016 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.012 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.006 | Remibrutinib | — uncovered |